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• Three most common DRAEs:
• Device-Related 
Thrombosis (n=25)
• Device Embolization (n=10)
• Device Migration (n=6)
• No significant difference in 
rates of DRAEs between 
both groups (<27 mm & ≥27 
mm).
•No significant difference 
in rates of device-related 
thrombosis, device 
migration, and device 
embolization between 
the two groups of WMF 
sizes (< 27mm vs ≥27).
•These findings should 
provide additional 
qualitative insight for 
management of WMF 
patients.
• Manufacturer And User Device 
Experience (MAUDE): FDA 
database containing self-reported 
adverse events for FDA-approved 
medical devices. Database 
queried for WMF-related events 
(Jan. 2020 – Jan. 2021).
• Case narratives analyzed for:
• Time Of Event Detection
• Device Size
• Device-Related Adverse Events 
(DRAE)




• DRAEs grouped by size (<27 mm 
vs. ≥27 mm) for analysis using 
Fisher’s Exact; p-value <0.05 was 
considered statistically significant.
Device-Related Adverse Events From WATCHMAN FLX Implants As
Reported By The Food And Drug Administration
Dongjin Suh, B.S.1, Paul E. Kim, B.S.2, Emmanuel Magsino, M.S.1, Tae Shik Park, M.D.3
Virginia Commonwealth University School of Medicine1, Liberty University College of Osteopathic Medicine2, Virginia Commonwealth University Health System3
• WATCHMAN FLX (WMF): left 
atrial appendage closure device 
for the prevention of intracardiac 
thrombosis in non-valvular atrial 
fibrillation patients. FDA-approved 
in July 2020.
• Studies on the previous model 
(WATCHMAN) suggest a potential 
association between device size 
and device-related thrombosis.[1]
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Device-Related Thrombosis 5 (20.8%) 20 (40%) 0.122
Device Embolization 2 (8.3%) 8 (16%) 1.000
Device Migration 2 (8.3%) 4 (8%) 0.484
Table 1. Comparison of DRAE rates based on WMF device size (<27 mm & ≥27 mm)
WATCHMAN FLX 27 mmWATCHMAN 27 mm
Figure 1. Total number of DRAEs counted from reports that included device size and time of event detection
Image 1. WATCHMAN & WATCHMAN FLX [2]
OBJECTIVE
To characterize common 
device-related 




MAUDE database does not 
account for all WMF placements 




















Post-Procedure Recovery (PPR), Post-Discharge Follow-Up (PDF)
PPR &
PDF
(n=41)
Intra-
operative
(n=17)
Device-Related Thrombosis (n=5)
Device Embolization (n=2)
Device Migration (n=2)
